We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 97

Competition Bureau releases updated IP enforcement guidelines and white paper on patent litigation settlement agreements

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • October 7 2014

The Competition Bureau made several significant announcements in September that affect the pharmaceuticals and life sciences sectors. On September 18

Consolidated CETA text released Patent term restoration and innovator right of appeal in PM(NOC) proceedings part of EU trade agreement

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • October 6 2014

On September 26, 2014, after five years of negotiations, the Comprehensive Economic and Trade Agreement (CETA) consolidated text was finally released

Pharma in brief - Federal Court of Appeal overturns Federal Court decision and dismisses application for prohibition order

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • July 2 2014

Pharmascience Inc. (Pharmascience) appealed from the decision of Justice O’Keefe of the Federal Court (reported as AstraZeneca Canada Inc. v

Federal Court grants injunction that allows infringing biologic drug to stay on the market

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 20 2014

Case: AbbVie Corporation, AbbVie Deutschland GMBH & Co. KG and AbbVie Biotechnology Ltd. v. Janssen Inc., 2014 FC 489 Drug: Ustekinumab (STELARA®

Federal Court grants one of three prohibition applications for VIGAMOX eye drops containing moxifloxacin hydrochloride

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • June 1 2014

This latest decision from the Federal Court is consistent with a recent trend towards a more literal construction of patent claims. The Court

Federal Court finds the PMPRB has no jurisdiction over pricing of generic products

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • May 31 2014

Case: Sandoz Canada Inc

Court imposes cost sanctions for repeat litigation under NOC Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • May 27 2014

On May 1, 2014, the Federal Court dismissed Bayer’s application for an Order prohibiting the Minister of Health from issuing a Notice of Compliance

No retroactive access to section 8 - Supreme Court refuses to hear appeal to set aside earlier prohibition order in the face of later held patent invalidity

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • April 30 2014

On April 24, 2014 the Supreme Court of Canada (“SCC”) dismissed Apotex Inc.’s (“Apotex”) leave application on a Rule 399 motion to set aside a

“Perfect match” of claims and the authorized product required for patent listing under the NOC regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • April 11 2014

This was an application for judicial review of a decision of the Minister of Health (“Minister”) which denied the listing of Eli Lilly Canada Inc.’s

Federal Court of Appeal weighs in on section 8 damage quantification

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • March 27 2014

On March 14, 2014, the Federal Court of Appeal released two decisions with respect to proceedings commenced pursuant to section 8 of thePatented